Matthew Fust Biography and Net Worth

Director of Atara Biotherapeutics

Mr. Fust has served as a member of the Ultragenyx Board since January 2014. Currently, he is a Board member and an advisor to life sciences companies. Mr. Fust served as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. from January 2009 until January 2014, when he retired. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer of Jazz Pharmaceuticals, Inc. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves on the Board of Directors of Atara Biotherapeutics, Inc., and Crinetics Pharmaceuticals, Inc. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

What is Matthew K. Fust's net worth?: The estimated net worth of Matthew K. Fust is at least $197,181.00 as of October 18th, 2024. Mr. Fust owns 20,100 shares of Atara Biotherapeutics stock worth more than $197,181 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. Fust may own. Learn More about Matthew K. Fust's net worth.
How do I contact Matthew K. Fust?: The corporate mailing address for Mr. Fust and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on Matthew K. Fust's contact information.
Has Matthew K. Fust been buying or selling shares of Atara Biotherapeutics?: Matthew K. Fust has not been actively trading shares of Atara Biotherapeutics during the last ninety days. Most recently, Matthew K. Fust sold 534 shares of the business's stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $487.50, for a transaction totalling $260,325.00. Learn More on Matthew K. Fust's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 17,499 shares worth more than $204,878.87. The most recent insider tranaction occured on November, 18th when EVP Jill Henrich sold 1,000 shares worth more than $11,200.00. Insiders at Atara Biotherapeutics own 3.7% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 11/18/2024.

Matthew K. Fust Insider Trading History at Atara Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/4/2021	Sell	534	$487.50	$260,325.00
5/14/2018	Sell	491	$1,089.25	$534,821.75	792

Matthew K. Fust Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $9.81

$9.68

$10.60

50 Day Range

MA: $10.65

$7.78

$14.26

2 Week Range

Now: $9.81

$6.50

$39.50

Volume

76,980 shs

Average Volume

104,688 shs

Market Capitalization

$56.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

2025’s #1 Trump Trade

From The Oxford Club | Ad

All the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies Set to See Enormous Profit Potential.

Details Here.